OptiNose, Inc. (OPTN)
NASDAQ: OPTN · Real-Time Price · USD
0.670
-0.006 (-0.90%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.

The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.

The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

OptiNose, Inc.
OptiNose logo
Country United States
Founded 2010
IPO Date Oct 13, 2017
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 132
CEO Ramy Mahmoud

Contact Details

Address:
1020 Stony Hill Road, Suite 300
Yardley, Pennsylvania 19067
United States
Phone 267 364 3500
Website optinose.com

Stock Details

Ticker Symbol OPTN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001494650
CUSIP Number 68404V100
ISIN Number US68404V1008
Employer ID 42-1771610
SIC Code 2834

Key Executives

Name Position
Dr. Ramy A. Mahmoud M.D., M.P.H. Chief Executive Officer and Director
Michael F. Marino Esq. Chief Legal Officer and Corporate Secretary
Paul Spence Chief Commercial Officer
P. Terence Kohler Chief Financial Officer
Anthony J. Krick Vice President of Finance and Chief Accounting Officer
Jonathan Neely Vice President of Investor Relations and Business Development
Karen E. Brophy Chief Human Resources Officer and Vice President of Human Resources

Latest SEC Filings

Date Type Title
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 16, 2024 8-K Current Report
Oct 8, 2024 8-K Current Report
Sep 25, 2024 8-K Current Report
Sep 16, 2024 144 Filing
Sep 16, 2024 144 Filing
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 15, 2024 144 Filing
Jul 15, 2024 144 Filing